KR101835040B1 - Cosmetic composition for improving rosacea comprising herbal extract - Google Patents

Abstract

The present invention relates to a cosmetic composition for improving injection or whitening, which comprises a herbal medicine extract having excellent visage and whitening function.
INDUSTRIAL APPLICABILITY According to the present invention, by producing a cosmetic product using a herbal medicine extract, it is possible to improve symptoms of skin erythema induced by ovulation.
Also, according to the present invention, by producing a cosmetic product using a herbal medicine extract, it is possible to inhibit the production of melanin and reduce the content of melanin, thereby improving the whitening function.

Description

[0001] Cosmetic composition for improving rosacea containing herbal extract [

The present invention relates to a cosmetic composition for improving injection or whitening comprising an extract of a herbal medicine, and more particularly to a cosmetic composition for improving injection or whitening comprising a herbal medicine extract which is excellent in improving visa and whitening function.

Rosacea is a chronic skin disease that occurs mainly in the middle of the face of the nose and cheeks. It is a major symptom of the reddened face and vasodilatation. It is sometimes caused by papules (bulging skin lesions less than 1 cm in size), pustules (pus) And it is a chronic skin disease that spreads to the scalp and upper body when it gets worse.

The definite cause is not clear yet, and it is presumed that the disease is related to vasomotor function abnormality in that most of the injected patients have abnormal vascular control function or migraine headache for heat or various stimuli. Chronic sunlight is also thought to be caused by sunlight. Dermatophyte collagen fibers and elastic fibers are denatured by expansion of blood vessels, flushing, erythema and capillary dilatation, and dermatophytes are denatured and fibrosis may occur.

A family history of injection appears in 30-40% of patients. If one of the parents has an injection, it is not necessarily the case that the injection is inherited to the child, but if someone in the household has an injection, the likelihood of injecting is higher than for those who do not. To date, there is no conclusive evidence that heredity is the cause of injection. There are several types of injections with various clinical manifestations. Both sexes are seen in all ages after teenager, but they are most common in 30s and 50s and occur more frequently in women, but severe symptoms appear mainly in men.

Injection is carried out in several stages. At the onset of the onset, only symptoms of redness appear on the face. These redness may be caused by various nonspecific stimuli such as ultraviolet radiation, heat, cold, chemical stimulation, strong emotional upset, alcohol, hot or irritating Food and the like. When these nonspecific stimuli are given, red spots accompanied by tingling or burning symptoms may be observed, and red spots may last from several hours to several days.

Injection is difficult to treat, depending on the severity and severity of the illness. Treatment depends on the use of 0.75% metronidazole gel, and imidazole-based medicines for the treatment of fungal diseases are often used. This is not because the fungus is involved in the cause of the injection, but because it reduces the inflammation and suppresses the immune function, which is presumed to be effective.

In addition, ointments used in the treatment of acne are often used. Eating medicine usually uses tetracycline-based antibiotics, but tetracycline should be taken three times a day, and the disadvantage is that the gastrointestinal disorder appears well.

Natural remedy is difficult, and the treatment of injections, which are repeatedly improved and deteriorated, has the problem of adverse effects due to long-term antibiotic use. Therefore, there is an urgent need for research that can efficiently improve the injection disease while minimizing the use of chemicals.

The present invention relates to a cosmetic composition for improving injection or whitening, which can improve the symptoms of skin erythema induced by ophthalmologic examination by producing a cosmetic using a herbal medicine extract.

The present invention also relates to a cosmetic composition for improving injection or whitening which can inhibit the production of melanin by producing a cosmetic using a herbal medicine extract.

In addition, the present invention includes a herbal medicine extract which can reduce the melanin content and improve the whitening function by lowering the activity of tyrosinase, which plays an important role in the synthesis of melanin, by producing a cosmetic product using a herbal medicine extract To a cosmetic composition for improving injection or for whitening.

The cosmetic composition for improving injection or whitening according to the present invention may be used for improving injection or whitening cosmetic composition according to the present invention. The cosmetic composition for improving injection or whitening according to the present invention may contain at least one selected from the group consisting of Seiho, Rhizoma, Rhizoma, Rhubarb, Rhizomes, And extracts of herbal medicines extracted from herbal medicines containing ginger, control, gyeongryeong, phytase, hwanggi, peony, and licorice.

In the cosmetic composition for improving injection or whitening according to the present invention, the herbal medicine extract may contain at least one selected from the group consisting of Seiho, horse mackerel, rhododendron, rhododendron, chrysanthemum, yellowtail, gardenia, safflower, The process of extracting the herbal medicines containing ginseng, dermis, ginseng root, ginger, control, gyeongryeo, taxa, hwanggi, peony, and licorice from water at 70 ~ 100 ℃ for 2-5 hours is repeated 2 ~ 6 times To obtain an extract, followed by lyophilization.

In the cosmetic composition for improving or whitening an injection according to the present invention, the herbal medicines are preferably used in an amount of 0.5 to 2.5% by weight, 0.5 to 2.5% by weight of horseback rid, 0.5 to 2.5% by weight of rhizome, 0.5 to 2.5% 1.5 to 3.0% by weight of Rhizobium, 1.5 to 3.0% by weight of Rhizobium, 1.5 to 3.0% by weight of Gardenia, 1.5 to 3.0% by weight of Safflower, 2.0 to 4.0% by weight of Gold, 2.0 to 4.0% 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% 3.5 to 5.5% by weight of the composition, 3.5 to 5.5% by weight of the control, 5.0 to 7.0% by weight of the ginseng, 5.0 to 7.0% by weight of Tatsa, 5.0 to 7.0% by weight of sulfur, 8.0 to 10.0% .

In the cosmetic composition for improving injection or whitening according to the present invention, the herbal medicine extract is contained in an amount of 0.1 to 5% by weight based on the total weight of the cosmetic composition.

In the cosmetic composition for improving or for whitening according to the present invention, the cosmetic composition further comprises sillymarin.

In the cosmetic composition for improving injection or whitening according to the present invention, it is preferable that the formulation of the cosmetic composition is at least one selected from the group consisting of lotion, lotion, nutritional cream, massage cream, mist, essence, gel, serum, pack, powder, ointment for skin, A hair lotion, a shampoo, a suspension, an emulsion, a spray or a serum.

INDUSTRIAL APPLICABILITY According to the present invention, by producing a cosmetic product using a herbal medicine extract, it is possible to improve symptoms of skin erythema induced by ovulation.

Also, according to the present invention, by producing a cosmetic product using a herbal medicine extract, it is possible to inhibit the production of melanin and reduce the content of melanin, thereby improving the whitening function.

1 is a graph showing the cytotoxicity of B16F10 cell line of herbal medicine extract according to the present invention.
2 is a graph showing the effect of inhibiting melanin formation by the herbal medicine extract according to the present invention.
3 is a graph showing intracellular tyrosinase activity of the herbal medicine extract according to the present invention.
FIGS. 4A, 4B, and 4C are graphs showing the expression of MITF, TYRP1, and TYRP2 mRNA in the B16F10 cell line by the herbal medicine extract according to the present invention. FIG.
5a and 5b are graphs showing the effect of the cosmetic comprising the herbal medicine extract according to the present invention on skin flare by the degree of flare and the size of flare, respectively, and Fig. 5c is a graph showing that the cosmetic containing the herb extract This is a photo taken of the effect.
FIG. 6 is a photograph showing the effect of the cosmetic comprising the herbal medicine extract on the skin tissue state according to the present invention. FIG.

The details of other embodiments are included in the detailed description and drawings.

BRIEF DESCRIPTION OF THE DRAWINGS The advantages and features of the present invention and the manner of achieving them will become apparent with reference to the embodiments described in detail below with reference to the accompanying drawings. The present invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein.

Hereinafter, the present invention will be described with reference to the accompanying drawings.

The present invention relates to a method for preparing a medicament for the prevention and treatment of acne vulgaris, comprising the steps of: A cosmetic composition for improving injection or whitening comprising an extract of a herbal medicine extracted from a herbal medicament containing herbicide, peony, and licorice. The herb medicine used in the present invention is preferably the above-mentioned herbal medicine, but the type of herbal medicine is not limited thereto and may be selectively used including a herbal medicine commonly used in the art.

In the cosmetic composition for improving or whitening an injection according to the present invention, the herbal medicines are preferably used in an amount of 0.5 to 2.5% by weight, 0.5 to 2.5% by weight of horseback rid, 0.5 to 2.5% by weight of rhizome, 0.5 to 2.5% 1.5 to 3.0% by weight of Rhizobium, 1.5 to 3.0% by weight of Rhizobium, 1.5 to 3.0% by weight of Gardenia, 1.5 to 3.0% by weight of Safflower, 2.0 to 4.0% by weight of Gold, 2.0 to 4.0% 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% by weight of ginseng, 3.5 to 5.5% Wherein the composition comprises 3.5-5.5% by weight of the composition, 3.5-5.5% by weight of the composition, 5.0-7.0% by weight of the composition, 5.0-7.0% by weight of the composition, 5.0-7.0% by weight of sulfur, 8.0-10.0% . In the cosmetic composition for improving injection or whitening according to the present invention, the herbal medicine extract may contain at least one selected from the group consisting of Seiho, horse mackerel, rhododendron, rhododendron, chrysanthemum, yellowtail, gardenia, safflower, The process of extracting the herbal medicine containing ginseng, dandelion, ginger, ginger, control, gyeongryeo, taxa, hwanggi, peony, and licorice at a temperature of 10 ~ 30L at 70 ~ 100 ℃ for 2 ~ 6 times to obtain an extract, followed by lyophilization.

In the cosmetic composition for improving or whitening an injection according to the present invention, the herbal medicine extract is contained in an amount of 0.1 to 5% by weight, preferably 0.5 to 3% by weight based on the total weight of the cosmetic composition. When the herbal medicine extract is added in an amount of less than 0.1% by weight, the effect of inhibiting melanin formation and alleviation of skin erythema symptoms due to ovulation can be insufficient. If the extract of herbal medicine exceeds 5% by weight, cytotoxicity may occur.

In the cosmetic composition for improving or for whitening according to the present invention, the cosmetic composition further comprises silymarin.

In the cosmetic composition for improving injection or whitening according to the present invention, the formulation of the cosmetic composition may be at least one selected from the group consisting of lotion, lotion, nutritional cream, massage cream, mist, essence, gel, serum, pack, powder, ointment for external use, A hair lotion, a shampoo, a suspension, an emulsion, a spray or an essence.

The cosmetic composition for improving injection or whitening according to the present invention is prepared by using the herbal medicinal extract according to the present invention and at least one additive generally used for the production of cosmetics. The additives included in the cosmetic composition of the present invention include mineral oil, cetyl ethylhexanoate, butyleneglycol, cetyl alcohol, glyceryl stearate, phage-100 stearate, polysorbate, dimethicone, glyceryl stearate But are not limited to, sodium lauryl sulfate, sodium lauryl sulfate, sodium lauryl sulfate, lactose, microcrystalline wax, sorbitan stearate, sodium hyaluronate, phenoxyethanol, betaine, fragrance, carbomer, clophenethine, sodium hydroxide, It is preferable to use purified water. However, the type of the additive is not necessarily limited thereto, but it may be mixed with the herbal medicine extract and used in an appropriate amount as long as the effect of the present invention is not inhibited.

In addition, the herbal medicine extracts contained in the herbal medicine extract used in the cosmetic preparation using the cosmetic composition for anti-smudge or whitening according to the present invention may be selected from the group consisting of rooibos extract, asai palm extract, aronia fruit extract, green tea extract, , Ginseng callus culture extract, mung bean germ cell culture extract, green tea callus culture extract, ginseng extract, peony extract, ginseng extract, golden extract, rhizome extract, green tea extract, ginkgo leaf extract, peach leaf extract, white pattern thistle extract, Yeast / licorice extract fermentation filtrate.

Hereinafter, the present invention will be described in more detail by way of examples.

< Example  1 to 12: Herbal medicine  The physiological activity of the extract>

[ Herbal medicine  Preparation of extract]

1.99% by weight of horse mackerel, 1.49% by weight of horse mackerel, 1.49% by weight of rhubarb, 1.24% by weight of rhubarb, 2.24% by weight of chrysanthemum, 2.24% by weight of yellowish white, 2.24% by weight of gardenia, 2.24% by weight of safflower, 2.99% 4.48% by weight of ginseng, 4.48% by weight of ginseng, 4.48% by weight of ginger root, 4.48% by weight of ginger root, 4.48% by weight of ginger root, 4.48% by weight of root ginger, 4.48% , 5.97% by weight of Taebaek, 5.97% by weight of Pharmacia, 5.97% by weight of Porphyry, 8.96% by weight of Peony and 8.96% by weight of Licorice were added to 20 L of water and the mixture was pressure-extracted at 100 ° C for 3 hours. . Then, the above extracts were collected and lyophilized to obtain a herbal medicine extract.

Experiments for measuring the physiological activity of the herbal medicine extract of the present invention were carried out as follows.

[Cell culture]

The B16F10 melanin cell line used in the present invention was cultured in Dulbecco's modified eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), which was purchased from Korean Cell Line Bank (KCLB, Seoul, Korea) And cultured in a CO2 incubator (MCO-17A1, Sanyo, Japan) at 37 ° C and 5% CO2.

[Cytotoxicity measurement]

B16F10 cells were seeded at 5 × 10 3 cells / well in 96 wells, and the cells were stabilized for 24 hours, and the herbal extracts were treated at different concentrations. After incubation for 72 hours, 1/10 of the cell culture solution was added to the MTS solution, and the mixture was incubated at 37 ° C for 2 hours. Then, ELISA microplate reader (Infinite 200 pro, TECAN Ltd., Mannheim, Switzerland) Absorbance was measured at 490 nm.

[ Intracellular Tyrosinase  Activity measurement]

B16F10 cells were seeded at 5 × 10 4 cells / well in 6 wells, and the cells were stabilized for 24 hours. Then, the extracts of herb extracts were treated at different concentrations. After 1 hour, α-MSH was treated to 100 nM and cultured for 72 hours Respectively. The cells were washed twice with PBS, treated with RIPA protein lysis buffer, and incubated at 4 ° C for 30 minutes. After that, tyrosinase activity was measured by centrifugation at 4 ° C at 13000 rpm for 30 minutes, with only protein supernatant. The amount of protein was measured by ELISA at 595 nm through Bradford (1976), and L-DOPA was treated with the same protein and the intracellular tyrosinase activity was measured at 540 nm absorbance.

[Measurement and observation of melanin]

B16F10 cells Cells were seeded at a density of 5 × 10 4 cells in a 60-mm dish, and each extract was pretreated for 1 hour at a concentration of 100 μM and cultured for 72 hours. Then, the cells were harvested by treatment with trypsin-EDTA twice, and the cells were collected at 3000 rpm for 5 minutes. After removing the supernatant, the cells were treated with 1N NaOH solution to which 10% dimethyl sulfoxide (DMSO) Lt; 0 &gt; C for 1 hour. Quantification of melanin was measured by synthesized melanin using an ELISA microplate reader at 410 nm.

[Whitening-related gene expression time PCR ]

To confirm the expression of the whitening-related gene, B16F10 cells were seeded at 1 × 10 5 cells / well in a 60 mm dish and cultured for 24 hours. Each extract was treated with various concentrations for 1 hour and induced to produce melanin by α-MSH (100 nM), cultured for 24 hours, washed twice with PBS and harvested.

 RNA was isolated from the harvested cells using Tripura Isolation Reagent (Roche Diagnostics, Mannheim, Germany). 5 쨉 g of mRNA was synthesized with cDNA using a High Capacity cDNA Reverse Transcription Kit (Applied Biosystem, Foster City, CA). The experiment was carried out according to the manufacturer's manual. 1 μl of synthesized cDNA, 1 μl of taqman primer, 10 μl of Taqman Universal Master Mix II (Applied Biosystem, Foster City, CA, USA) and 8 μl of tertiary distilled water were added, and real time PCR instrument (ABI 7500, Applied Biosystem , Foster City, CA). The information of the TaqMan agent used in the quantitative polymerase reaction is shown in Table 1 below. The real-time PCR reaction was repeated 40 times at 50 ° C for 2 minutes, 95 ° C for 10 minutes, denaturation at 95 ° C for 15 seconds, and annealing temperature at 60 ° C for 15 seconds.

Gene symbol Gene description TaqMan Gene Expression Analysis Number Reference sequence MITF Microphthalmia-associated transcription factor Mm00434954_m1 ㎚_001113198.1 TYRP1 Tyrosinase-related protein 1 Mm00453201_m1 ㎚_001282014.1 DCT (TYRP2) Dopachrome tautomerase Mm01225584_m1 Nm_010024.3 HPRT Hypoxanthine guanine-guanine phospholiposyl transferase
phosphoribosyl transferase)
(Reference gene) Mm01545399_m1 Nm_013556.2

[Statistical processing]

The results obtained in this experiment are shown as the mean ± SD (mean ± SD), and the mean difference between the control and each experimental group was analyzed by Student's t-test (Student's t-test) There were statistically significant differences.

< Experimental Example  One: Herbal medicine  Extract B16F10  Evaluation of cytotoxicity against cell lines>

In Experimental Example 1, the cytotoxicity of the extract of herb medicine was evaluated in B16F10 cell line. For the evaluation of cytotoxicity, the herbal medicine extract of the present invention was administered to B16F10 cells in Example 1 (125 μg / ml), Example 2 (250 μg / ml) and Comparative Example 1 (500 μg / ml) And Comparative Example 2 (1000 μg / ml). The results are shown in FIG. 1, and MTS was treated after 24 hours. 1 is a graph showing the cytotoxicity of B16F10 cell line of herbal extracts. 1, reference numeral 125 denotes Example 1, reference numeral 250 denotes Example 2, reference numeral 500 denotes Comparative Example 1, and reference numeral 1000 denotes Comparative Example 2, while reference numerals in Figs.

Experimental conditions of Examples and Comparative Examples of Experimental Example 1 are as follows.

In Example 1 and Example 2, the cytotoxicity of B16F10 cells was evaluated by injecting herbal extracts of the present invention at 125 and 250 μg / ml, respectively.

In Comparative Example 1 and Comparative Example 2, cytotoxicity of B16F10 cells was evaluated by injecting herbal extracts of the present invention at 500 and 1000 μg / ml, respectively.

1, when cytotoxicity was not observed when 125 ~ 250 μg / ml of the herbal medicine extract of the present invention was injected as in Examples 1 and 2, the herbal medicine extract was injected at a high concentration of 500 and 1000 μg / ml In Comparative Example 1 and Comparative Example 2, cytotoxicity was shown. Therefore, when the herbal medicine extract is excessively injected, cytotoxicity may occur, which may adversely affect the skin, which is undesirable.

< Experimental Example  2: Herbal medicine  Inhibitory Effect of Extracts on Melanin Production>

In Experimental Example 2, the effect of the herbal medicine extract on the melanin biosynthesis in the B16F10 cell line was examined. In order to evaluate the inhibitory effect on melanin formation, the herbal medicine extract of the present invention was administered to B16F10 cells in the same manner as in Example 3 (125 μg / ml), Example 4 (250 μg / ml) and Comparative Example 3 / ml) and Comparative Example 4 (62.5 μg / ml), respectively. In the case of treatment with 100 nM of α-MSH alone as Reference Example 1 and with 100 μg / ml of arbutin as Reference Example 2, ml was added to the culture medium to further inhibit melanin formation. The melanin content of each of the above concentrations of herbal medicine extract and arbutin was treated with B16F10 cell line and treated with α-MSH for 1 hour to induce melanogenesis and cultured for 72 hours. The results are shown in FIG. 2 is a graph showing the inhibitory effect on melanin formation of a herbal medicine extract. For reference, FIG. 2 shows a control example in which the blank is not subjected to any treatment, reference symbol 1 denotes α-MSH, reference symbol 2 denotes Arbutin, 31.3 denotes comparative example 3, 62.5 denotes comparative example 4, 3, and 250 represents Example 4.

Experimental conditions of Examples and Comparative Examples of Experimental Example 2 are as follows.

In Example 3 and Example 4, melanin content was measured by adding 125 and 250 μg / ml of herbal extracts of the present invention, respectively, to confirm melanin formation inhibitory effect.

In Comparative Example 3 and Comparative Example 4, the melanin production inhibitory effect was confirmed by measuring the melanin content by injecting the herbal medicine extract of the present invention at 31.3 and 62.5 μg / ml, respectively.

2, when 125 ~ 250 μg / ml of the herbal medicine extract of the present invention was treated as in Example 3 and Example 4, compared to Reference Example 1 in which only α-MSH was treated without adding the herbal medicine extract, melanin And the content was remarkably decreased. However, in the case of Comparative Examples 3 and 4 in which the herbal medicine extracts of the present invention were added at 31.3 and 62.5 μg / ml, respectively, melanin content was decreased compared with Reference Example 1 in which only α-MSH alone was treated, However, the amount of decrease is small and does not appear to have a significant effect on the improvement of the injection disease. Therefore, when the herbal medicine extract is injected in an insufficient amount as in Comparative Examples 3 and 4, the melanin formation inhibitory effect is weak.

< Experimental Example  3: Herbal medicine  Extract Intracellular  Measurement of tyrosinase activity>

Melanin is known to be synthesized on the surface of the organs called melanomas, and tyrosinase enzyme plays an important role in the synthesis of melanin. In Experimental Example 3, the intracellular tyrosinase activity was confirmed in order to examine the effect of the herbal medicine extract of the present invention on the increased tyrosinase activity by α-MSH. In order to measure the activity of the tyrosinase, the herbal medicine extract of the present invention was administered to B16F10 cells in the same manner as in Example 5 (125 μg / ml), Example 6 (250 μg / ml) and Comparative Example 5 (31.3 μg / ml ) And Comparative Example 6 (62.5 μg / ml), respectively. In the case of treatment with 100 nM of α-MSH alone as Reference Example 3 and 100 μg / ml of arbutin as Reference Example 4, The results are shown in FIG. 3. FIG. 3 shows the results of experiments in which one case of intracellular tyrosinase activity was further tested. 3 is a graph showing intracellular tyrosinase activity of herbal extracts. For reference, FIG. 3 shows a control example in which the blank is not subjected to any treatment, the? -MSH in Reference Example 3, the Arbutin in Reference Example 4, the 31.3 in Comparative Example 5, the 62.5 in Comparative Example 6, 5, and 250 represents Example 6.

Experimental conditions of Examples and Comparative Examples of Experimental Example 3 are as follows.

In Example 5 and Example 6, intracellular trocinase activity was measured by injecting the herbal medicine extract of the present invention at 125 and 250 μg / ml, respectively.

In Comparative Example 5 and Comparative Example 6, the intracellular trocinase activity was measured by adding 31.3 and 62.5 μg / ml of the herbal medicine extract of the present invention, respectively.

Referring to FIG. 3, it was confirmed that the activity of tyrosinase was increased by α-MSH (Reference Example 3), 125 to 250 μg / ml of the herbal extract of the present invention was treated as in Example 5 and Example 6 When the activity of tyrosinase was measured, it was confirmed that the herbal medicine extract of the present invention can lower the increased tyrosinase activity by α-MSH. This suggests that the herbal medicine extract of the present invention inhibits the activity of tyrosinase to reduce the melanin content. Thus, the herbal medicine extract of the present invention has a reduced melanin content and thus has a whitening function.

On the other hand, in Comparative Example 5 and Comparative Example 6 in which the herbal medicine extracts were treated with 31.3 and 62.5 μg / ml, respectively, the activity of the tyrosinase was decreased as compared with Reference Example 3 in which α-MSH alone was treated, However, it is understood that the reduction amount is smaller than those of Examples 5 and 6, and 125 to 250 μg / ml of the herbal medicine extract is more effective for the improvement of the injection disease.

< Experimental Example  4: B16F10  In the cell line Herbal medicine  By extract TYRP1 , MITF , TYRP2 mRNA  Expression effect>

In Experimental Example 4, the effect of the herbal medicine extract of the present invention on the expression of genes MITF, TYRP1 and TYRP2 mRNA associated with melanin pigment regulation was examined. TYRP1 and TYRP2 are known to increase expression by MITF transcription factors and are known to be involved in melanin biosynthesis. In Experimental Example 4, in order to examine the effect of the herbal medicine extract of the present invention on the expression of such genes, α-MSH and the herbal medicine extract of the present invention were treated with B16F10 cell line and gene expression was confirmed by real-time PCR after 24 hours.

For this experiment, in Example 4, the herbal medicine extract of the present invention was administered to B16F10 cells in accordance with Examples 7, 9 and 11 (125 μg / ml), Examples 8, 10 and 12 (250 μg / ml) TYRP1, and TYRP2 gene expression levels were measured in the same manner as in Example 9, 11 and 11 (31.3 μg / ml) and Comparative Examples 8, 10 and 12 (62.5 μg / ml), respectively. In addition, the degree of gene expression when α-MSH alone was treated as Reference Examples 5, 7, and 9 and when it was treated with arbutin as Reference Examples 6, 8, and 10 was also measured, MITF mRNA expression), 4b (TYRP1 mRNA expression) and 4c (TYRP2 mRNA expression). FIGS. 4A, 4B, and 4C are graphs showing the expression of MITF, TYRP1, and TYRP2 mRNA in the B16F10 cell line by the herbal extract. FIG. For reference, FIGS. 4A, 4B and 4C show a control example in which no blank is processed, reference symbols A, B and C are reference examples 5, 7 and 9, reference symbols Arbutin are reference examples 6, 8 and 10, Comparative Examples 7, 9 and 11, 62.5 and Comparative Examples 8, 10 and 12, respectively, and Examples 125, 125 and 125 respectively show Examples 8, 10 and 12, respectively.

Experimental conditions of Examples and Comparative Examples of Experimental Example 4 are as follows.

In Example 7 and Example 8, the extracts of herbal medicine of the present invention were injected at 125 and 250 μg / ml, respectively, and the degree of MITF gene expression was measured.

In Example 9 and Example 10, the degree of TYRP1 gene expression was measured by injecting the herbal medicine extract of the present invention at 125 and 250 μg / ml, respectively.

In Examples 11 and 12, the degree of expression of TYRP2 gene was measured by injecting herbal extracts of the present invention at 125 and 250 μg / ml, respectively.

In Comparative Example 7 and Comparative Example 8, the herbal extract extract of the present invention was added at 31.3 and 62.5 μg / ml, respectively, and the degree of MITF gene expression was measured.

In Comparative Example 9 and Comparative Example 10, the degree of TYRP1 gene expression was measured by injecting the herbal medicine extract of the present invention at 31.3 and 62.5 μg / ml, respectively.

In Comparative Example 11 and Comparative Example 12, the degree of TYRP2 gene expression was measured by injecting the herbal medicine extract of the present invention at 31.3 and 62.5 μg / ml, respectively.

Referring to FIG. 4A, it was confirmed that the concentration of MITF mRNA increased by α-MSH decreased when the herbal extract extracts of the present invention were treated with 125-250 μg / ml as in Examples 7 and 8. Therefore, it was found that the herbal medicine extract of the present invention effectively inhibited gene expression of MITF at 125 ~ 250 μg / ml and was effective for whitening function. On the other hand, in Comparative Example 7 and Comparative Example 8 in which the herbal medicine extract was added in an amount of 31.3 to 62.5 μg / ml, there was no inhibitory effect on MITF gene expression, which is not desirable for whitening function.

Referring to FIG. 4B, it was confirmed that the concentration of mRNA of TYRP1 increased by α-MSH decreased when 125 ~ 250 μg / ml of the herbal extract of the present invention was treated as in Example 9 and Example 10 . Therefore, it was found that the herbal medicine extract of the present invention effectively inhibited the expression of TYRP1, which is a mechanism of tyrosinase production, at 125 to 250 μg / ml. On the other hand, mRNA levels of TYRP1 in Comparative Example 9 and Comparative Example 10, in which the herbal medicine extract was added at 31.3 to 62.5 μg / ml, were relatively lower than those of α-MSH to suppress the expression of TYRP1, The effect is less than that of arbutin, which is known to be inhibitory. In addition, the mRNA level of TYRP1 was reduced by a small amount compared with those of Examples 9 and 10, and 125 ~ 250 μg / ml of herbal extract was more effective for improving the injection disease.

Referring to FIG. 4C, when the mRNA level of TYRP2 increased by α-MSH was treated with 125 ~ 250 μg / ml of the herbal extract of the present invention as in Examples 11 and 12, the concentration decreased . On the other hand, mRNA levels of TYRP2 in Comparative Example 11 and Comparative Example 12, in which the herbal medicine extract was added at 31.3 to 62.5 μg / ml, were relatively lower than those of α-MSH, indicating that TYRP2 expression was suppressed, The effect is less than that of arbutin, which is known to be inhibitory. In addition, as compared with Example 11 and Example 12, mRNA levels of TYRP2 were decreased to a small extent, and 125 ~ 250 μg / ml of herbal extract was more effective for improving the injection disease.

< Example  13 to 16: Herbal medicine  Physiological Activity of Cosmetic Composition Including Extract>

Experiments for measuring the effect of the cosmetic composition for improving injection or whitening comprising the herbal medicine extract of the present invention were carried out as follows.

First, in order to measure the effects of the cosmetic composition for improving injection or whitening comprising the herbal medicine extract of the present invention, creams, lotions, essences, and toners were prepared and tested as described below.

cosmetics Production Example 1 . Manufacture of cream

The cosmetic composition for improving injection or whitening comprising the herbal medicine extract of the present invention is prepared by using the herbal medicine extract according to the present invention and at least one additive generally used for manufacturing cosmetics. Such additives may be used in an appropriate amount by mixing with the herbal medicine extract insofar as the effect of the present invention is not inhibited.

 Ingredients and contents of the additives used in the production of the cream in the present cosmetic preparation example 1 were 4.51% by weight of mineral oil, 1.19% by weight of cetylhexylhexanoate, 0.19% by weight of butylene glycol, 3.58% by weight of cetyl alcohol, 0.35% by weight of stearate, 0.18% by weight of phage-100 stearate, 1.64% by weight of polysorbate 60, 0.30% by weight of dimethicone, 0.48% by weight of glyceryl stearate S, 0.99% by weight of microcrystalline wax, 1.11 wt.% Of sodium hyaluronate, 0.20 wt.% Of phenoxyethanol, 0.60 wt.% Of betaine, 0.80 wt.% Of perfume, 0.34 wt.% Of carbomer, 0.15 wt.% Of clophenethine, 0.14 wt. And the remaining amount of the total amount of the composition is 1.00% by weight, and the remaining amount of the total amount of the composition is 0.03% by weight, tocopheryl acetate 0.03% by weight, disodium edetate 0.21% by weight and silymarin 1.00% Waterways filled to prepare a cream.

For reference, the ingredient contents of each of the herbal medicine extracts used in the production of cream in the present cosmetic preparation example 1 are as follows.

2.24% by weight of Rhodiola extract, 2.24% by weight of Huangyan extract, 2.24% by weight of gardenia extract, 2.24% by weight of safflower extract, 1.24% by weight of safflower extract, 2.99% by weight of the golden extract, 2.99% by weight of the extract of Wuin, 2.99% by weight of the extract of Guan Qiang, 4.48% by weight of the extract of Zyunghyang, 4.48% 4.48% by weight of extract, 4.48% by weight of ganoderma extract, 4.48% by weight of ginger extract, 4.48% by weight of jujube extract, 5.97% by weight of ganoderma extract, 5.97% The weight was put into a nonwoven fabric and put into 20 L of water. The mixture was pressure-extracted twice at 100 ° C for 3 hours and lyophilized to obtain a herbal extract, and 1.00% by weight was used for the cream.

The kinds of herbal medicines contained in the herbal medicine extracts are not limited thereto, but the types of herbal medicines contained in the herbal medicine extracts are not limited thereto. Rooibos extract, Asai palm extract, Aronia fruit extract, Green tea extract, Gamooki callus culture extract, Ginseng callus culture extract, Extracts of Ganoderma lucidum, Ganoderma lucidum extract, Ganoderma lucidum extract, Ganoderma lucidum extract, Golden extract, Rhus vernicifolia extract, Green tea extract, Ginkgo biloba extract, Peach leaf extract, White pattern thistle extract, Aspergillus / yeast / licorice extract fermentation filtrate .

cosmetics Production Example 2 . Manufacture of lotions

The cosmetic composition for improving injection or whitening of the herbal medicine extract of the present invention is prepared by using the herbal medicine extract according to the present invention and at least one additive which is generally used for the production of cosmetics. Such additives may be used in an appropriate amount by mixing with the herbal medicine extract insofar as the effect of the present invention is not inhibited.

Ingredients and contents of additives used in the production of lotion in the present cosmetic preparation example 2 were 3.55% by weight of mineral oil, 0.23% by weight of butylene glycol, 1.19% by weight of cetylhexylhexanoate, 1.64% by weight of polysorbate 60, 0.47 wt.% Glyceryl stearate, 0.32 wt.% Phage-100 stearate, 2.89 wt.% Cetyl alcohol, 0.30 wt.% Dimethicone, 0.34 wt.% Phenoxyethanol, 0.48 wt.% Glyceryl stearate, 1.11 wt.%, Betaine 0.60 wt.%, Sodium hyaluronate 1.05 wt.%, Fragrance 0.99 wt.%, Carbomer 0.34 wt.%, Clophenethine 0.25 wt.%, Tocopheryl acetate 0.03 wt.%, Sodium hydroxide 0.14 wt. 0.21% by weight of disodium diatomite, 1.00% by weight of silymarin, and 1.00% by weight of the herbal medicine extract and the remaining amount of the total amount of the composition were filled with purified water to prepare a lotion.

For reference, the content of each of the herbal medicine extracts used in the production of lotion in the present cosmetic preparation example 2 is as follows.

2.24% by weight of Rhodiola extract, 2.24% by weight of Huangyan extract, 2.24% by weight of gardenia extract, 2.24% by weight of safflower extract, 1.24% by weight of safflower extract, 2.99% by weight of the golden extract, 2.99% by weight of the extract of Wuin, 2.99% by weight of the extract of Guan Qiang, 4.48% by weight of the extract of Zyunghyang, 4.48% 4.48% by weight of extract, 4.48% by weight of ganoderma extract, 4.48% by weight of ginger extract, 4.48% by weight of jujube extract, 5.97% by weight of ganoderma extract, 5.97% The weight was put into a nonwoven fabric and put into 20 L of water. The mixture was pressure-extracted twice at 100 ° C. for 3 hours and freeze-dried to obtain a herbal extract, and 1.00% by weight was used for lotion preparation.

The kinds of herbal medicines contained in the herbal medicine extracts are not limited to them, and include rooibos extract, asai palm extract, aronia fruit extract, green tea extract, aspergillus / yeast / licorice extract fermented filtrate, turmeric callus culture extract, Extracts, mung bean germ cell culture extract, green tea callus culture extract, and white pattern thistle extract.

cosmetics Production Example 3 . Manufacture of essences

The cosmetic composition for improving injection or whitening comprising the herbal medicine extract of the present invention is prepared by using the herbal medicine extract according to the present invention and at least one additive generally used for manufacturing cosmetics. Such additives may be used in an appropriate amount by mixing with the herbal medicine extract insofar as the effect of the present invention is not inhibited.

Ingredients and contents of the additives used in the production of the essence in the present cosmetic preparation example 3 were 0.20% by weight of butylene glycol, 4.48% by weight of ethanol, sodium hyaluronate, ceramide 3, 0.68% by weight of betaine, 0.18% by weight of hydrogenated castor oil, 0.22% by weight of phenoxyethanol, 1.25% by weight of allantoin, 1.11% by weight of sodium polyacrylate, 0.34% by weight of clophenethine, 0.80% by weight of fragrance, 0.22% 1.00% by weight of silymarin, and 1.00% by weight of the herbal medicine extract and the remaining amount of the total amount of the herbal medicine extract were filled with purified water to prepare an essence.

For reference, the content of each of the herbal medicine extracts used in the production of the essence in the present cosmetic preparation example 3 is as follows.

2.24% by weight of Rhodiola extract, 2.24% by weight of Huangyan extract, 2.24% by weight of gardenia extract, 2.24% by weight of safflower extract, 1.24% by weight of safflower extract, 2.99% by weight of the golden extract, 2.99% by weight of the extract of Wuin, 2.99% by weight of the extract of Guan Qiang, 4.48% by weight of the extract of Zyunghyang, 4.48% 4.48% by weight of extract, 4.48% by weight of ganoderma extract, 4.48% by weight of ginger extract, 4.48% by weight of jujube extract, 5.97% by weight of ganoderma extract, 5.97% The weight was put into a nonwoven fabric and put into 20 L of water. The mixture was pressure-extracted twice at a temperature of 100 ° C for 3 hours and then lyophilized to obtain a herbal extract, and 1.00% by weight was used for preparing the essence.

The types of herbal medicines contained in the herbal medicine extracts are not limited to them, and examples thereof include aspergillus / yeast / licorice extract fermentation filtrate, rooibos extract, asai palm extract, Aronia fruit extract, green tea extract, Extracts, mung bean germ cell culture extract, green tea callus culture extract, and white pattern thistle extract.

cosmetics Production Example 4 . Manufacture of Toner

The cosmetic composition for improving injection or whitening comprising the herbal medicine extract of the present invention is prepared by using the herbal medicine extract according to the present invention and at least one additive generally used for manufacturing cosmetics. Such additives may be used in an appropriate amount by mixing with the herbal medicine extract insofar as the effect of the present invention is not inhibited.

In the cosmetic preparation example 4 of the present invention, the ingredients and the contents of the additives used in the preparation of the toner were 1.25% by weight of butylene glycol, 5.20% by weight of ethanol, 1.05% by weight of sodium hyaluronate, 0.60% by weight of betaine, -60 Hydrogenated castor oil 0.18 wt% Phenoxyethanol 0.31 wt% Allantoin 1.25 wt% Clofenesin 0.20 wt% Fragrance 0.80 wt% Sodium polyacrylate 0.14 wt% Disodium iodide 0.22 wt% %, And silymarin 1.00% by weight. In addition to the above additives, 1.00% by weight of the herbal medicine extract and the remaining amount of the total amount of the composition were filled with purified water to prepare a toner.

For reference, the ingredient content of the herbal medicine extract used in the production of the toner in the cosmetic preparation example 4 is as follows.

2.24% by weight of Rhodiola extract, 2.24% by weight of Huangyan extract, 2.24% by weight of gardenia extract, 2.24% by weight of safflower extract, 1.24% by weight of safflower extract, 2.99% by weight of the golden extract, 2.99% by weight of the extract of Wuin, 2.99% by weight of the extract of Guan Qiang, 4.48% by weight of the extract of Zyunghyang, 4.48% 4.48% by weight of extract, 4.48% by weight of ganoderma extract, 4.48% by weight of ginger extract, 4.48% by weight of jujube extract, 5.97% by weight of ganoderma extract, 5.97% The weight was put into a nonwoven fabric and put into 20 L of water. The mixture was pressure-extracted twice at 100 ° C. for 3 hours and freeze-dried to obtain a herbal extract, and 1.00% by weight was used for toner preparation.

The kinds of herbal medicines contained in the herbal medicine extracts are not limited thereto, but the types of herbal medicines contained in the herbal medicine extracts are not limited thereto. Rooibos extract, Asai palm extract, Aronia fruit extract, Green tea extract, Gamooki callus culture extract, Ginseng callus culture extract, An extract, a white patterned thistle extract, an aspergillus / yeast / licorice extract fermentation filtrate.

Examples of the formulations for improving injections or whitening cosmetics containing the herbal medicines according to the present invention include lotions, lotions, nutritional creams, massage creams, mist, essences, gels, serums, packs, powders, ointments for external use, soaps, A hair lotion, a shampoo, a suspension, an emulsion, a spray or a serum, and the examples of the cosmetic preparation and the following examples are illustrative of the present invention, but the content of the present invention is not limited by the following examples.

[Experimental Animals]

Five-week-old Balb / c mice were purchased from Samutoco and subjected to a purification procedure for about one week before the experiment. During the experiment, the animals were kept in an environment where the temperature of 22 ± 1 ℃ and the humidity of 55 ± 10% were maintained in the animal breeding room of the oriental medicine industry promotion institute.

[Production of mouse model inducing osteoporosis]

After about a week of purification, the hair was removed using a razor. After 1 day, 40 .mu.L of the LL-37 peptide and 320 .mu.M of the peptide were intradermally injected (id) into the hairless areas in Reference Examples 11 and 13, respectively. As a positive control, metronidazole cream was applied to Reference Examples 12 and 14, respectively. On the other hand, 40 l of DW was added to the normal group in place of the LL-37 peptide. (Comparative Examples 13 and 16), 0.3 weight% (Comparative Examples 14 and 17) and 0.5 weight% (Comparative Examples 15 and 18) were added to the cosmetics, Cosmetic products for cosmetic parts (Examples 13 and 15) containing extracts, herbal medicine extracts and cosmetic products for cosmetic parts containing silymarin (Examples 14 and 16) were also applied by the same method. This process was induced two times a day for two days. After that, the symptoms were observed 48 hours after the first administration.

[Symptom observation]

Photographs were taken of the degree of induction of the ovary, and the degree of symptom was evaluated for the color and size of the redness. Symptom observation The degree of induction of the ovary was photographed and the degree of symptom was evaluated by the color and size of the flushing.

[Histopathological analysis]

After the end of the experiment, the area of the back of the spine was excised and immersed in 10% formalin fixative for 24 hours. After the tissue was embedded in paraffin, the tissue was cut into a 4-μm-thick microtome (Leica, Germany) and adhered onto a slide glass. The tissues on the slide were removed with water using alcohol and xylene, and H & E (haematoxylin-eosin) staining, which identifies neutrophils / eosinophils, and IHC (immunohistochemistry) Respectively.

[Statistical processing]

The results obtained in this experiment are shown as the mean ± SD (mean ± SD). The mean difference between the control group and each experimental group was analyzed by Student's T-test. When the p-value was less than 0.05, statistically significant difference .

< Experimental Example  5: LL In a 37-lead injection model Herbal medicine  The cosmetic composition containing the extract On a flare  Impacts>

Experimental Example 5 is an experiment for confirming the effect of a cosmetic composition containing a herbal medicine extract on skin redness in an injection model induced by LL-37. In order to evaluate the effect of the herbal medicine extract on skin erythema, in Example 5, a cosmetic composition containing the herbal medicine extract according to the present invention (as in Examples 13 and 14) in a model of inflammatory skin disease induced by LL-37 Example 13), and the cosmetic composition containing both the herbal medicine extract and the silymarin according to the present invention (Example 14) and the cosmetic composition containing only silymarin as in Comparative Examples 13 to 15 As shown in Example 12, the case where metronidazole, which is a general injection disease treatment, is applied is described. After treating the cosmetics of the above Examples and Comparative Examples for 2 days, the redness score and the redness area, which are apparent symptoms according to the elapsed time, were measured. The results are shown in FIGS. 5A, 5B and 5C, respectively. FIGS. 5A and 5B are graphs showing the effect of the substances of Examples 13 and 14 and Comparative Examples 13 to 15 on the skin redness in terms of the degree of redness and the size of redness, respectively. FIG. 5C is a graph showing the results of Examples 13 and 14, 15 &lt; / RTI &gt;

5A, 5B and 5C are photographs of the normal group, reference example 11 in which LL-37 alone was treated with LL-37 alone, and reference example 11 in which LL-37 was treated with metronidazole in LL- Example 12 was prepared in the same manner as in Example 1 except that 0.1% by weight, 0.3% by weight of silymarin was added to LL-37, and LL-37 + Sil-0.1, LL- , "LL-37 + Co" was prepared in the same manner as in Example 13, except that LL-37 was treated with 0.5 wt% + Sil-0.1 "shows Example 14 in which LL-37 was treated with both 0.1% by weight of the herbal medicine extract and 0.1% by weight of silymarin.

Experimental conditions of Examples and Comparative Examples of Experimental Example 5 are as follows.

In Example 13, the cosmetic composition containing 1.00% by weight of the herbal medicine extract of the present invention was applied to an injection model induced by LL-37, treated for 2 days, and the degree of injection induction was plotted or photographed .

In Example 14, a cosmetic composition containing 0.1% by weight of the herbal medicine extract of the present invention and 0.1% by weight of silymarin was applied to an injection model induced by LL-37, treated for 2 days, FIG.

Reference Example 12 is a reference example in which metronidazole, which is a therapeutic agent for injection diseases, is applied to LL-37-induced injection model and treated for 2 days, and the degree of injection induction is shown in a graph or photographed.

In Comparative Example 13, Comparative Example 14, and Comparative Example 15, the silymarin extract was applied to the injection model induced by LL-37 at a concentration of 0.1% by weight, 0.3% by weight and 0.5% by weight for 2 days, Are shown in graphs or photographed as comparative examples.

5A, 5B, and 5C, it can be seen that the degree and size of skin redness due to the injection symptom of skin are alleviated in Example 13 ("LL-37 + Co" in FIG. 5C) (Reference Example 12), which is a treatment for existing injection disease, metronidazole was used when the herbal medicine extract according to the present invention was used in combination with silymarin as in the case of "LL-37 + Co + Sil-0.1" As shown in the same effect, skin redness due to the injection symptoms of the skin is most apparent. On the other hand, in Comparative Example 13, Comparative Example 14, and Comparative Example 15, it was confirmed that the erythema symptoms were alleviated by concentration, as compared with LL-37 (Reference Example 11) It was shown that the same symptom as that of Example 14 was improved.

< Experimental Example  6: LL In a 37-lead injection model Herbal medicine  Effect of cosmetic composition containing extract on skin tissue status>

Experimental Example 6 is an experiment for confirming the effect of a cosmetic composition containing a herbal medicine extract on skin texture in an injection model induced by LL-37. Hematoxylin and eosin (H & E) staining was performed in Experimental Example 6 in order to evaluate the effect of the herbal extract on skin tissue condition. In Experimental Example 6, the cosmetic composition containing the herbal medicine extract according to the present invention (Example 15) and the cosmetic composition containing both the herbal medicine extract and the silymarin according to the present invention (Example 16) When the cosmetic composition containing silymarin was applied as in the case of Comparative Example 16 to 18, metronidazole, which is a general injection disease treatment agent, was applied as in Reference Example 14 to confirm the effect of the substances on the skin tissue state, The results are shown in Fig. FIG. 6 is a photograph showing the effect of the materials of Examples 15 and 16 and Comparative Examples 16 to 18 on skin tissue state. FIG.

Reference Example 13 in which LL-37 alone was treated with LL-37 alone, Reference Example 14 in which LL-37 was treated with metronidazole in &quot; LL-37 + 0.3% and 0.5% by weight of silymarin were added to LL-37, respectively, in terms of LL-37 + Sil-0.1, LL-37 + Sil-0.3 and LL- LL-37 + Co + Sil-0.1 &quot; obtained by treating Comparative Example 16, Comparative Example 17, and Comparative Example 18 treated with 1.00% by weight of the herbal medicine extract with LL- "Shows Example 16 in which LL-37 was treated with both 0.1% by weight of herbal extract and 0.1% by weight of silymarin.

Experimental conditions of Examples and Comparative Examples of Experimental Example 6 are as follows.

In Example 15, a cosmetic composition containing 1.00% by weight of the herbal medicine extract of the present invention was applied to an injection model induced by LL-37 to photograph the skin tissue state.

In Example 16, a cosmetic composition containing 0.1% by weight of the herbal medicine extract of the present invention and 0.1% by weight of silymarin was applied to an injection model induced by LL-37 to photograph the skin tissue state.

Reference Example 14 is a reference example in which metronidazole, which is a therapeutic agent for injectable disease, is applied to an injection model induced by LL-37 and the skin tissue state is photographed.

In Comparative Example 16, Comparative Example 17, and Comparative Example 18, the silymarin extract was applied to the injection model induced by LL-37 at 0.1 wt%, 0.3 wt%, and 0.5 wt% Yes.

Referring to FIG. 6, it can be seen that the skin tissue of the normal group (NOR) not treated with LL-37 has a clear boundary between the epidermis and the dermis, and the number of normal immune cells and the thickness of skin tissue are well preserved . On the other hand, in LL-37 (Reference Example 13) of FIG. 6 treated only with LL-37, the boundary between the epidermis and the dermis is very vague, and the number of immune cells is locally infiltrated and the skin tissue is thickened Respectively.

However, in Example 15 ("LL-37 + Co" in FIG. 6) and Example 16 ("LL-37 + Co + Sil-0.1" in FIG. 6), skin tissue did not become thick, And the skin erythema induced by LL-37 was alleviated. On the other hand, in Comparative Example 16, Comparative Example 17, and Comparative Example 18, the thickness of the skin tissue was not relatively thicker than that of LL-37, and the boundary between the epidermis and the dermis was divided. .

According to the present invention, by manufacturing a cosmetic product using a specific herbal medicine extract, it is possible to improve the skin erythema induced by vomiting, to inhibit the production of melanin and to reduce the melanin content, thereby improving the whitening function. In particular, by using the herbal medicine extract according to the present invention in combination with silymarin, it is possible to exert an excellent synergistic effect in improving the visage and whitening function.

It will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. It is therefore to be understood that the above-described embodiments are illustrative in all aspects and not restrictive. The scope of the present invention is defined by the appended claims rather than the foregoing detailed description, and all changes or modifications derived from the meaning and scope of the claims and the equivalents thereof are included in the scope of the present invention Should be interpreted.

Claims (6)

Ginseng, dandelion, ginseng, contrast, gyeongryeo, taxa, emperor, peony, and ginseng. In addition, the ginseng is a kind of ginseng. Wherein the herbal medicine extract is contained in an amount of 0.1 to 5% by weight based on the total weight of the composition. The method according to claim 1,
The herbal medicine extract
Ginseng, dandelion, ginseng, ginseng, contrast, gyeongryeo, phytophthora, phloem, phlox, phlox, phlox, phlox, phlox, And extracting the herbal medicine containing licorice at a temperature of 70 to 100 ° C for 2 to 5 hours by repeating the process twice or 6 times to obtain an extract and freeze-drying the extract. Or whitening cosmetic composition. 3. The method according to claim 1 or 2,
The herb medicine is added to the total weight of herbal medicines in an amount of 0.5 to 2.5% by weight, 0.5 to 2.5% by weight of horseback rid, 0.5 to 2.5% by weight of rhizome, 0.5 to 2.5% by weight of rhubarb, 1.5 to 3.0% 2.0 to 4.0% by weight of persimmon, 2.0 to 4.0% by weight of persimmon, 3.5 to 5.5% by weight of sorghum, 3.5 to 5.5% by weight of astragalus, 1.5 to 3.0% by weight of gardenia, 1.5 to 3.0% 3.5-5.5% by weight of ginseng, 3.5-5.5% by weight of ginseng, 3.5-5.5% by weight of dandelion, 3.5-5.5% by weight of dandelion, 3.5-5.5% by weight of gangrene, 3.5-5.5% by weight of ginger, 3.5-5.5% Wherein the cosmetic composition comprises 7.0 to 7.0% by weight of phytase, 5.0 to 7.0% by weight of phthalate, 5.0 to 7.0% by weight of sulfur, 8.0 to 10.0% by weight of peanut, and 8.0 to 10.0% by weight of licorice. delete 3. The method according to claim 1 or 2,
Wherein the cosmetic composition further comprises silymarin. 3. The method according to claim 1 or 2,
Characterized in that the formulation of the cosmetic composition is a lotion, lotion, nutritional cream, massage cream, mist, essence, gel, serum, pack, powder, soap, sponge, suspension, emulsion, &Lt; / RTI &gt;

Images